Yale School of Medicine: Phase 3 Results Add to Hope for Patients With Myelodysplastic Syndromes
December 05, 2023
December 05, 2023
NEW HAVEN, Connecticut, Dec. 5 (TNSres) -- The Yale University School of Medicine issued the following news:
By Michael Masciadrelli
For people living with certain blood cancers, including lower-risk myelodysplastic syndromes (LR-MDS), there are limited effective treatment options. This is especially true for MDS patients who are red blood cell transfusion-dependent (RBC-TD) and who do not respond to, or are not eligible for, the treatment typically used to stimulate bo . . .
By Michael Masciadrelli
For people living with certain blood cancers, including lower-risk myelodysplastic syndromes (LR-MDS), there are limited effective treatment options. This is especially true for MDS patients who are red blood cell transfusion-dependent (RBC-TD) and who do not respond to, or are not eligible for, the treatment typically used to stimulate bo . . .